학술논문

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study
Document Type
Article
Source
In The Lancet Haematology December 2018 5(12):e618-e627
Subject
Primary Research
Articles
Language
ISSN
2352-3026